The standard of care for relapsed or refractory Hodgkin lymphoma is autologous hematopoietic cell transplantation (HCT), while allogeneic HCT is a curative strategy for patients for whom autologous HCT is unsuccessful.A retrospective cohort study suggested that survival rates have increased in both transplantation settings from 2010 to 2022.Two-year relapse incidence decreased among patients in both settings, and 2-year non-relapse mortality marginally decreased or remained comparatively stable.
Outcomes have substantially improved over time in patients with relapsed or refractory classical Hodgkin lymphoma who underwent hematopoietic cell transplantation (HCT), according to a retrospective, registry-based cohort study.
Among patients undergoing their first autologous HCT, 2-year progression-free survival (PFS) rates increased from 63% in 2010-2014 to 73% in 2019-2022, while overall survival (OS) rates increased from 85% to 93%, reported Ali Bazarbachi, MD, of the American University of Beirut, and colleagues.
For those undergoing allogeneic HCT, 2-year PFS rates increased from 44% in 2010-2014 to 62% in 2019-2022, while 2-year OS rates increased from 66% to 72%, they wrote in Lancet Haematology.
